Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
Deep cervical lymphatic-venous anastomosis attenuates cognitive dysfunction and biomarker abnormalities in severe Alzheimer's disease: A prospective single-arm study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fu Xiaohong, Zhang Jing, Xiao Qiuxia, Li Tingting, Li Qijun, Zhang Shaofu, Zeng Wen, Gong Min, Cai Pan, Deng Zhaojian, Zhang Xuan, Xin Yuanjun, Su Liping, Tian Xiaohe, Wu Kaifeng, Xiong Liulin
Аннотация
INTRODUCTION: This study evaluated the efficacy of deep cervical lymphatic-venous anastomosis (dcLVA) for severe Alzheimer's disease (AD).
METHODS: A total of 139 severe AD patients undergoing dcLVA were enrolled, and changes in cognitive function and biomarkers were evaluated by comparing preoperative measures with postoperative outcomes over a 6-month follow-up period.
RESULTS: Patients undergoing dcLVA showed modestly elevated Mini-Mental State Examination (MMSE) scores from 48 hour postoperatively to 6-month follow-up. At 6-month, observable changes across functional status and neuropsychiatric symptoms were documented, as demonstrated by reductions in scores on the Activities of Daily Living (ADL) scale, Neuropsychiatric Inventory (NPI), Neuropsychiatric Inventory-Caregiver Distress (NPI-D), and Sleep Disorders Inventory (SDI). Biomarker analyses revealed decreased cerebrospinal fluid (CSF) β-amyloid (Aβ) 42, Aβ40, and p-Tau levels postoperatively, along with increased plasma concentrations of these markers. No deaths or serious procedure-related adverse events occurred during 6-month follow-up.
DISCUSSION: These findings suggest that dcLVA may confer multifaceted clinical benefits in severe AD patients, including attenuation of certain neuropsychiatric dysfunctions and a potential slowing of symptom progression.
METHODS: A total of 139 severe AD patients undergoing dcLVA were enrolled, and changes in cognitive function and biomarkers were evaluated by comparing preoperative measures with postoperative outcomes over a 6-month follow-up period.
RESULTS: Patients undergoing dcLVA showed modestly elevated Mini-Mental State Examination (MMSE) scores from 48 hour postoperatively to 6-month follow-up. At 6-month, observable changes across functional status and neuropsychiatric symptoms were documented, as demonstrated by reductions in scores on the Activities of Daily Living (ADL) scale, Neuropsychiatric Inventory (NPI), Neuropsychiatric Inventory-Caregiver Distress (NPI-D), and Sleep Disorders Inventory (SDI). Biomarker analyses revealed decreased cerebrospinal fluid (CSF) β-amyloid (Aβ) 42, Aβ40, and p-Tau levels postoperatively, along with increased plasma concentrations of these markers. No deaths or serious procedure-related adverse events occurred during 6-month follow-up.
DISCUSSION: These findings suggest that dcLVA may confer multifaceted clinical benefits in severe AD patients, including attenuation of certain neuropsychiatric dysfunctions and a potential slowing of symptom progression.